Lonza and **Bio*One Capital** Invests in Second Large Scale Commercial Mammalian Cell Culture Plant in Singapore

Lonza Group Ltd and Singapore’s Bio*One Capital had an agreement of joint venture to build a large-scale mammalian cell culture plant, Lonza Biologics Tuas, facility in Singapore for the manufacture of commercial biopharmaceuticals. This will be the second large-scale mammalian manufacturing plant in Singapore located in Tuas Biomedical Park, which have up to four mammalian bioreactor trains, each with a flexible capacity of 1’000 up to 20’000 liters and inclusive with respective purification units. The plant is being constructed over two phases. The construction of the Lonza Biologics Tuas shell, in the first phase, will be initiated in February 2007. The final build-out of the facility will be completed and become operational at the latest in 2011. When fully completed, Lonza Biologics Tuas expects to hire approximately 350 people for the operation.

Stefan Borgas, CEO of Lonza, commented: “By this project, Lonza continues to strengthen its leading position as the global custom manufacturer of biopharmaceuticals entering the fast growing Asian market. And facilitate with cutting edge technology with a skilled labor force. It will be able to manufacture products with a wide array of processes, yields and technologies.” They also offer their customers an additional site to complement their existing large scale Portsmouth, NH USA facility, and expand upon the capabilities to serve their clients in this fast growing market segment. With two large-scale biologics plants, Singapore is poised to become one of the world’s top manufacturing locations for biologics and to strengthen the sustainable competitive, highly technological and high quality manufacturing in general and the country’s excellent capabilities in GMP production of bulk actives for global pharmaceutical companies.

**About Lonza**

Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life sciences industries. Its products and services extend through its customers’ supply chain needs, from research and development to final product manufacture. Lonza is the global leader in the production and technical support of pharmaceutical active ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also a leading provider of value added chemical and biotech ingredients to the nutrition, hygiene, preservation, agrochemical and personal care markets.
About Bio*One Capital

Bio*One Capital is a leading, dedicated biomedical sciences investment management company in Asia with a worldwide presence. With funds of over US$600 million, investments are focused on promising and innovative global biomedical companies where Bio*One Capital can play a value adding role in bridging and supporting companies’ growth strategies in Asia through their operations in Singapore. A part of the Singapore Economic Development Board, Bio*One Capital oversees a portfolio of over 60 companies in US, Europe, Singapore and Asia.

Contact details:
Londa
Address: Lonza Ltd
Iwan Schroeter
Muenchensteinerstrasse 38
CH-4002 Basel
Switzerland
Tel: +41 61 316 82 98
Fax: + 41 61 316 92 98
URL: webfeedback(at)lonza.com

Contact details:
Bio*One Capital Pte Ltd
Address: 20, Biopolis Way
#09-01 Centros
Singapore 138668
Tel: +65 6395 7700
Fax: +65 6395 7796
Email: infoHQ@bio1capital.com
URL: www.bio1capital.com